Show simple item record

dc.contributor.authorSafrit, Jeffrey T.
dc.contributor.authorRuprecht, Ruth
dc.contributor.authorFerrantelli, Flavia
dc.contributor.authorXu, Weidong
dc.contributor.authorKitabwalla, Moiz
dc.contributor.authorVan Rompay, Koen
dc.contributor.authorMarthas, Marta
dc.contributor.authorHaigwood, Nancy
dc.contributor.authorMascola, John R.
dc.contributor.authorLuzuriaga, Katherine
dc.contributor.authorJones, Samuel Adeniyi
dc.contributor.authorMathieson, Bonnie J.
dc.contributor.authorNewell, Marie-Louise
dc.date2022-08-11T08:10:12.000
dc.date.accessioned2022-08-23T16:58:49Z
dc.date.available2022-08-23T16:58:49Z
dc.date.issued2004-02-01
dc.date.submitted2012-05-01
dc.identifier.citationJ Acquir Immune Defic Syndr. 2004 Feb 1;35(2):169-77.
dc.identifier.issn1525-4135 (Linking)
dc.identifier.pmid14722451
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43451
dc.description.abstractAntiretroviral therapy can profoundly reduce the risk of mother-to-child transmission (MTCT) of HIV, but the drugs have a relatively short half-life and should thus be administered throughout breast-feeding to optimally prevent postnatal infection of the infant. The potential toxicities and the development of resistance may limit the long-term efficacy of antiretroviral prophylaxis, and a safe and effective active/passive immunoprophylaxis regimen, begun at birth, and potentially overlapping with interpartum or neonatal chemoprophylaxis, would pose an attractive alternative. This review draws on data presented at the Ghent Workshop on prevention of breast milk transmission and on selected issues from a workshop specifically relating to immunoprophylaxis held in Seattle in October 2002. This purpose of this review is to address the scientific rationale for the development of passive (antibody) and active (vaccine) immunization strategies for prevention of MTCT. Data regarding currently or imminently available passive and active immunoprophylaxis products are reviewed for their potential use in neonatal trials within the coming 1-2 years.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=14722451&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://journals.lww.com/jaids/Fulltext/2004/02010/Immunoprophylaxis_to_Prevent_Mother_to_Child.12.aspx
dc.subject*AIDS Vaccines
dc.subjectAcquired Immunodeficiency Syndrome
dc.subjectAnimals
dc.subjectBreast Feeding
dc.subjectFemale
dc.subjectHIV Antibodies
dc.subjectHIV-1
dc.subjectHumans
dc.subjectImmunization, Passive
dc.subjectInfant, Newborn
dc.subjectInfectious Disease Transmission, Vertical
dc.subjectMilk, Human
dc.subjectPregnancy
dc.subjectImmunology and Infectious Disease
dc.subjectPediatrics
dc.titleImmunoprophylaxis to prevent mother-to-child transmission of HIV-1
dc.typeJournal Article
dc.source.journaltitleJournal of acquired immune deficiency syndromes (1999)
dc.source.volume35
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/peds_immunology/34
dc.identifier.contextkey2814364
html.description.abstract<p>Antiretroviral therapy can profoundly reduce the risk of mother-to-child transmission (MTCT) of HIV, but the drugs have a relatively short half-life and should thus be administered throughout breast-feeding to optimally prevent postnatal infection of the infant. The potential toxicities and the development of resistance may limit the long-term efficacy of antiretroviral prophylaxis, and a safe and effective active/passive immunoprophylaxis regimen, begun at birth, and potentially overlapping with interpartum or neonatal chemoprophylaxis, would pose an attractive alternative. This review draws on data presented at the Ghent Workshop on prevention of breast milk transmission and on selected issues from a workshop specifically relating to immunoprophylaxis held in Seattle in October 2002. This purpose of this review is to address the scientific rationale for the development of passive (antibody) and active (vaccine) immunization strategies for prevention of MTCT. Data regarding currently or imminently available passive and active immunoprophylaxis products are reviewed for their potential use in neonatal trials within the coming 1-2 years.</p>
dc.identifier.submissionpathpeds_immunology/34
dc.contributor.departmentProgram in Molecular Medicine
dc.contributor.departmentDepartment of Pediatrics
dc.source.pages169-77


This item appears in the following Collection(s)

Show simple item record